Additional training and the increased popularity of rare disease drug development in recent years appears to have overcome what was thought to be varying experience with the issue among the US Food and Drug Administration's new drug application assessors.
Peter Stein, director of the FDA's Office of New Drugs, who also is acting head of the OND rare disease...







